Cited by 208Organ Transplantation Techniques and OutcomesTransplantation: Methods and OutcomesRenal Transplantation Outcomes and Treatments

Liver transplantation immunology: immunosuppression, rejection, and immunomodulation

Open access
Montano-Loza, Aldo J., Rodríguez-Perálvarez, Manuel L., Pageaux, George-Philippe, Sanchez-Fueyo, Alberto, Feng, Sandy·2023·Journal of Hepatology

Abstract

Outcomes after liver transplantation have continuously improved over the past decades, but long-term survival rates are still lower than in the general population. The liver has distinct immunological functions linked to its unique anatomical configuration and to its harbouring of a large number of cells with fundamental immunological roles. The transplanted liver can modulate the immunological system of the recipient to promote tolerance, thus offering the potential for less aggressive immunosuppression. The selection and adjustment of immunosuppressive drugs should be individualised to optimally control alloreactivity while mitigating toxicities. Routine laboratory tests are not accurate enough to make a confident diagnosis of allograft rejection. Although several promising biomarkers are being investigated, none of them is sufficiently validated for routine use; hence, liver biopsy remains necessary to guide clinical decisions. Recently, there has been an exponential increase in the use of immune checkpoint inhibitors due to the unquestionable oncological benefits they provide for many patients with advanced-stage tumours. It is expected that their use will also increase in liver transplant recipients and that this might affect the incidence of allograft rejection. Currently, the evidence regarding the efficacy and safety of immune checkpoint inhibitors in liver transplant recipients is limited and cases of severe allograft rejection have been reported. In this review, we discuss the clinical relevance of alloimmune disease, the role of minimisation/withdrawal of immunosuppression, and provide practical guidance for using checkpoint inhibitors in liver transplant recipients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2023.01.030

Cites

165 of 165 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Montano-Loza, A. J., Rodríguez-Perálvarez, M. L., Pageaux, G.-P., Sanchez-Fueyo, A., & Feng, S.
Affiliations
  • Université de Montpellier (FR)
  • University of California, San Francisco (US)
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2023-06
Volume
78
Issue
6
Pages
1199-1215
ISSN
0168-8278 (ISSN-L)
OpenAlex
W4376866235
Cited by
208
References
165
Citations by year
2026: 76 · 2025: 74 · 2024: 51 · 2023: 7
FWCI
13.46
Type
journal article
Language
en
Open access
Locations
  • Journal of Hepatology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Medical Research Council (MR/P007694/1)
Topics
  • Health Sciences › Medicine › Surgery › Organ Transplantation Techniques and Outcomes
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
  • Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
Keywords
liver transplantation, immunosuppression, allograft rejection, immunomodulation, immunosuppression withdrawal, immune checkpoint inhibitors, liver biopsy, rejection biomarkers, alloreactivity, transplant recipient survival
MeSH terms
Immune Checkpoint Inhibitors, Graft Rejection, Humans, Immunosuppression Therapy, Immunosuppressive Agents, Liver, Transplantation Immunology, Liver Transplantation, Immunomodulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review